ESMO: Gilead’s Trodelvy Outperforms Expectations In Breast Cancer, Again
Executive Summary
The company is presenting overall survival data in HR+/HER2- breast cancer from the TROPiCS-02 at ESMO. Oncology clinical development head Bill Grossman talked with Scrip about how it differs from rival Enhertu.